Cited by 43Alzheimer's disease research and treatmentsPhytoestrogen effects and researchDementia and Cognitive Impairment Research

Anti-amyloidoGenic Effects of Soybean Isoflavones In Vitro: Fluorescence Spectroscopy Demonstrating Direct Binding to Aβ Monomers, Oligomers and Fibrils

Open access
Hirohata, Mie, Ono, Kenjiro, Takasaki, Jun-ichi, Takahashi, Ryoichi, Ikeda, Tokuhei, Morinaga, Akiyoshi, Yamada, Masahito·2012·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Abstract

Alzheimer's disease is characterized by the presence of extracellular deposits of amyloid, primarily composed of the amyloid β-protein (Aβ). A growing body of evidence indicates that oligomeric forms of Aβ play a critical role in disease causation. Soybean isoflavones are flavonoids with an isoflavone backbone. Isoflavones have been reported to protect against Aβ-induced neurotoxicity in cultured cell systems, the molecular mechanisms remain unclear. Our previous studies demonstrated that red wine-related flavonoids with a flavone backbone are able to inhibit Aβ assembly and destabilize preformed Aβ aggregates. Here, we show that isoflavones, especially glycitein and genistein, have anti-fibrillization, anti-oligomerization and fibril-destabilizing effects on Aβ(1-40) and Aβ(1-42)in vitro at physiological pH and temperature, by using nucleation-dependent polymerization monitored by thioflavin T fluorescence, atomic force microscopy, electron microscopy, and photo-induced cross-linking of unmodified proteins followed by SDS-PAGE. Our three-dimensional fluorescence spectroscopic analyses demonstrated that glycitein interacted with Aβ monomers, oligomers and fibrils, indicating specific binding of glycitein to these Aβ species. Glycitein also interacted with different Aβ fragments (Aβ(1-42), Aβ(1-40), Aβ(1-16) and Aβ(25-35)), exhibiting the highest fluorescence enhancement with Aβ(25-35). We speculated that glycitein's anti-amyloidogenic properties are specifically mediated by its binding to Aβ monomers, oligomers and fibrils. Isoflavones may hold promise as a treatment option for preventative strategies targeting amyloid formation in Alzheimer's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbadis.2012.05.006

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hirohata, M., Ono, K., Takasaki, J.-I., Takahashi, R., Ikeda, T., Morinaga, A., & Yamada, M.
Affiliations
Kanazawa University (JP)
Corresponding author
Yamada, Masahito
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Publisher
Elsevier BV
Published
2012-08
Volume
1822
Issue
8
Pages
1316-1324
ISSN
0925-4439 (ISSN-L)
OpenAlex
W2074581769
Cited by
43
References
34
Citations by year
2026: 4 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 3 · 2020: 4 · 2019: 1 · 2018: 3 · 2017: 1 · 2015: 4 · 2014: 4 · 2013: 2 · 2012: 1
FWCI
2.36
Type
journal article
Language
en
Open access
Locations
  • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Knowledge Cluster Initiative [High-Tech Sensing and Knowledge Handling Technology (Brain Technology)]
  • Grant-in-Aid for Scientific Research (B) (20390242)
  • Japanese Ministry of Education, Culture, Sports, Science and Technology, Japan
  • Ministry of Health, Labour, and Welfare, Japan (M.Y.)
  • Novartis Foundation for Gerontological Research
  • Nagao Memorial Foundation
  • Alumni Association of the School of Medicine at Showa University
  • Fuji Foundation for Protein Research
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Phytoestrogen effects and research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
soy isoflavones, glycitein, genistein, amyloid-beta, Alzheimer's disease, amyloid oligomers, amyloid fibrils, protein-protein binding, amyloid beta 25-35, flavonoids, thioflavin T
MeSH terms
Humans, Isoflavones, Microscopy, Electron, Peptide Fragments, Glycine max, Spectrometry, Fluorescence, Thiazoles, Amyloid beta-Peptides, Microscopy, Atomic Force, Benzothiazoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review